Copyright
©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Diabetes. Mar 15, 2022; 13(3): 129-149
Published online Mar 15, 2022. doi: 10.4239/wjd.v13.i3.129
Published online Mar 15, 2022. doi: 10.4239/wjd.v13.i3.129
Markers of insulin resistance in Polycystic ovary syndrome women: An update
Chantal Anifa Amisi, Endocrinology and Diabetes Unit, Department of Medicine, Universita Campus Bio-medico di Rome, Rome 00128, Italy
Author contributions: Chantal Amisi wrote the manuscript.
Conflict-of-interest statement: The author declares that she has no conflicts of interest.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Chantal Anifa Amisi, MD, PhD, Doctor, Senior Researcher, Endo
Received: February 28, 2021
Peer-review started: February 28, 2021
First decision: July 15, 2021
Revised: September 14, 2021
Accepted: February 22, 2022
Article in press: February 22, 2022
Published online: March 15, 2022
Processing time: 379 Days and 17.4 Hours
Peer-review started: February 28, 2021
First decision: July 15, 2021
Revised: September 14, 2021
Accepted: February 22, 2022
Article in press: February 22, 2022
Published online: March 15, 2022
Processing time: 379 Days and 17.4 Hours
Core Tip
Core Tip: Diagnosing insulin resistance in Polycystic ovary syndrome is of crucial importance for better management and prevention of complications. Seeking of an easy-to-detect surrogate marker of insulin resistance represents a promising approach for maximizing treatment outcomes. This review highlights markers of insulin resistance already used in women with Polycystic ovary syndrome, including new markers recently reported in literature, and establishes a new classification of them.